28 results
8-K
EX-99.1
CADL
Candel Therapeutics Inc
29 Nov 22
Regulation FD Disclosure
8:31am
Exhibit 99.1
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
New clinical data to be presented from the Company’s phase 2 clinical … viral immunotherapies, today announced it will host a virtual Research and Development (R&D) Day from 11:00 am – 1:30 pm ET on Tuesday, December 6
8-K
EX-99.1
CADL
Candel Therapeutics Inc
30 Mar 23
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
8:30am
in solid tumor models.
On December 6, 2022, Candel hosted its R&D Day during which the Company’s leadership team and renowned external experts … and valacyclovir in combination with continued PD-1/PD-L1 agents in patients with late-stage NSCLC at the Company’s R&D Day. The data demonstrated evidence of local
8-K
CADL
Candel Therapeutics Inc
6 Dec 22
Regulation FD Disclosure
8:01am
Research and Development (R&D) Day from 11:00 am – 1:30 pm ET. The event will provide an extensive overview of the Company’s viral immunotherapy … 9.01
Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number
Description
R&D Day Corporate Presentation dated December 6, 2022
Cover Page
8-K
EX-99.1
CADL
Candel Therapeutics Inc
10 Nov 22
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
8:30am
Candidates in Solid Tumor Models
Upcoming clinical data presentations at SITC and SNO Annual Meetings
Virtual R&D Day on December 6, 2022, with Candel … and their CAR-T cells in solid tumors. We will close the year with new clinical results coming from our pipeline being presented at R&D Day and we look
8-K
CADL
Candel Therapeutics Inc
6 Dec 22
Other Events
5:30pm
and Development (R&D) Day. The event provided an extensive overview of the Company’s viral immunotherapy approach and oncology-focused pipeline, with new data
8-K
EX-99.1
jdv0jn4 ot2zie
6 Dec 22
Regulation FD Disclosure
8:01am
8-K
4tlzkx5xv pbq5wnd9
29 Nov 22
Regulation FD Disclosure
8:31am
8-K
EX-99.1
7mi92pe49gn
17 Apr 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Non-Small Cell Lung Cancer
8:30am
8-K
EX-99.1
aatqptbp698948im7
6 Dec 22
Other Events
5:30pm
8-K
EX-99.1
ohcg4
13 Jun 23
Based on forthcoming completion of patient enrollment and duration of follow-up in Cohort 2 from the phase 2 trial in late-stage NSCLC
8:31am
8-K
bs9rpyypke6od zxu9
17 Apr 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Non-Small Cell Lung Cancer
8:30am
8-K
EX-99.1
x05mdbrxkk15a4
26 Sep 23
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
8:30am
S-1
EX-10.7
iof9fd
25 Jun 21
IPO registration
5:28pm
S-1/A
EX-10.7
rqxmcq febh
16 Jul 21
IPO registration (amended)
6:07am
DEF 14A
emab4es9gq07ry xg6jb
2 Sep 22
Definitive proxy
8:30am